Willow Biosciences (TSX:WLLW) Debt-to-Equity : 1.32 (As of Mar. 2024)

View and export this data going back to 1983. Start your Free Trial

What is Willow Biosciences Debt-to-Equity?

Willow Biosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was C$0.67 Mil. Willow Biosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was C$1.36 Mil. Willow Biosciences's Total Stockholders Equity for the quarter that ended in Mar. 2024 was C$1.54 Mil. Willow Biosciences's debt to equity for the quarter that ended in Mar. 2024 was 1.32.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Willow Biosciences's Debt-to-Equity or its related term are showing as below:

TSX:WLLW' s Debt-to-Equity Range Over the Past 10 Years
Min: -3.31 Med: 0.04 Max: 1.32
Current: 1.32

During the past 13 years, the highest Debt-to-Equity Ratio of Willow Biosciences was 1.32. The lowest was -3.31. And the median was 0.04.

TSX:WLLW's Debt-to-Equity is ranked worse than
90.08% of 847 companies
in the Drug Manufacturers industry
Industry Median: 0.3 vs TSX:WLLW: 1.32

Willow Biosciences Debt-to-Equity Historical Data

The historical data trend for Willow Biosciences's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Willow Biosciences Debt-to-Equity Chart

Willow Biosciences Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.05

-1.56

0.03

0.04

0.63

Willow Biosciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.04	0.24	0.29	0.63	1.32

Competitive Comparison of Willow Biosciences's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Willow Biosciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Willow Biosciences's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Willow Biosciences's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Willow Biosciences's Debt-to-Equity falls into.

Willow Biosciences Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Willow Biosciences's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.731	+	1.425)	/	3.436
	=	0.63

Willow Biosciences's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.671	+	1.361)	/	1.544
	=	1.32

Willow Biosciences (TSX:WLLW) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Willow Biosciences Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Willow Biosciences's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Willow Biosciences (TSX:WLLW) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Willow Biosciences Inc (TSX:WLLW) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

CANSF:USA

Address

202, 1201 5th Street SW, Calgary, AB, CAN, T2R 0Y6

Website

https://www.willowbio.com

Willow Biosciences Inc is a Canadian biotechnology company. It has only one reportable segment engaged in developing and producing high-purity, plant-derived ingredients for consumer care, food and beverage, and pharmaceutical products. Geographically, it derives a majority of its revenue from Canada.

Executives

Patricia Ranija Choudhary

Director

Willow Biosciences (TSX:WLLW) Headlines

No Headlines